Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$96.38Cboe Real-Time Last Sale as of 12:48PM ET 7/06/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.92(1.95%)
Bid (Size)$96.34 (10)
Ask (Size)$96.63 (114)
Day Low / High$96.10 - 98.95
Volume235.6 K
 

View Biotechnology IndustryPeer Comparison as of 07/06/2022

 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $96.38
Change: -1.92 (1.95%)
Volume: 235.6 K
12:48PM ET 7/06/2022
 
 

Exact Sciences Corp ( NASDAQ )

Price: $43.71
Change: -0.69 (1.55%)
Volume: 1.1 M
12:50PM ET 7/06/2022
 
 

Exelixis Inc ( NASDAQ )

Price: $21.49
Change: -0.78 (3.50%)
Volume: 968.7 K
12:50PM ET 7/06/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Halozyme Therapeutics Inc ( NASDAQ )

Price: $45.66
Change: -0.67 (1.45%)
Volume: 360.2 K
12:44PM ET 7/06/2022
 

Read more news Recent News

Research Alert: CFRA Keeps Hold Opinion On Shares Of Neurocrine Biosciences
1:55PM ET 6/10/2022 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Jefferies Assumes Neurocrine Biosciences at Buy with $112 Price Target
10:15AM ET 6/06/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $75 to $150, according to analysts polled by Capital IQ....

Neurocrine Biosciences to Repurchase $179.4 Million of Convertible Notes
3:04AM ET 5/25/2022 MT Newswires

Neurocrine Biosciences (NBIX) entered into privately negotiated transactions to repurchase about $179.4 million of its existing 2.25% convertible senior...

Neurocrine Biosciences Gets FDA's Orphan Drug Designation for Experimental Huntington Disease Drug
3:42AM ET 5/13/2022 MT Newswires

Neurocrine Biosciences (NBIX) said late Thursday the US Food and Drug Administration granted an orphan drug designation to valbenazine for the potential...

Company Profile

Business DescriptionNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA. View company web site for more details
Address12780 El Camino Real
San Diego, California 92130
Phone+1.858.617.7600
Number of Employees585
Recent SEC Filing06/29/20224
Chief Executive Officer & DirectorKevin Charles Gorman
Vice President-Information Technology & OperationsBill Wilson
Chief Financial OfficerMatthew C. Abernethy
Chief Research OfficerDimitri E. Grigoriadis

Company Highlights

Price Open$97.61
Previous Close$98.30
52 Week Range$71.88 - 108.02
Market Capitalization$9.2 B
Shares Outstanding95.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings137.85
Earnings per Share$1.21
Beta vs. S&P 500N/A
Revenue$451.2 M
Net Profit Margin5.91%
Return on Equity5.30%

Analyst Ratings as of 04/21/2022

Buy
13
Overweight
3
Hold
9
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset